Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marc Dror Michaelson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Marc Michaelson and Matthew Smith.
Connection Strength

3.737
  1. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213.
    View in: PubMed
    Score: 0.381
  2. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20; 25(9):1038-42.
    View in: PubMed
    Score: 0.351
  3. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 01; 107(3):530-5.
    View in: PubMed
    Score: 0.336
  4. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005 Nov 10; 23(32):8219-24.
    View in: PubMed
    Score: 0.320
  5. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol. 2004 Oct 15; 22(20):4233-4.
    View in: PubMed
    Score: 0.297
  6. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2705-8.
    View in: PubMed
    Score: 0.287
  7. The role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep. 2003 May; 5(3):245-9.
    View in: PubMed
    Score: 0.268
  8. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2003; 21:547-64.
    View in: PubMed
    Score: 0.262
  9. Prostate cancer: metastatic. Clin Evid. 2002 Dec; (8):881-90.
    View in: PubMed
    Score: 0.261
  10. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2002; 20:471-91.
    View in: PubMed
    Score: 0.245
  11. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int. 2014 Dec; 114(6b):E25-E31.
    View in: PubMed
    Score: 0.146
  12. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):317-24.
    View in: PubMed
    Score: 0.142
  13. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94.
    View in: PubMed
    Score: 0.133
  14. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012 Nov; 53(11):1670-5.
    View in: PubMed
    Score: 0.128
  15. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5.
    View in: PubMed
    Score: 0.110
  16. Prostate cancer (metastatic). Clin Evid. 2003 Dec; (10):1012-22.
    View in: PubMed
    Score: 0.070
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.